A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer

1. Clamp, A.
2. Adams, M.
3. Atkinson, R.
4. Boven, E.
5. Calvert, A.H.
6. Cervantes, A.
7. Ganesan, T.
8. Lotz, J.
9. Vasey, P.
10. Cheverton, P.
11. Jayson, G.C.